3 Reasons Novavax Stock Could Double in 2018

Charles Dickens' introduction to A Tale of Two Cities sort of applies to Novavax's (NASDAQ: NVAX) experience in 2017 so far: "It was the best of times, it was the worst of times..."

At two different points this year, the biotech stock sat on year-to-date gains of 20% or more. But at three other times, Novavax's share price was down 20% or more for the year.

Despite its topsy-turvy moves over the last 11 months or so, next year could shape up to be much better for Novavax. I even think there's a realistic chance that the stock could double in value by the end of 2018. Here are three reasons that could happen.

Source: Fool.com